Telix Pharmaceuticals (TLX) announces a strategic clinical collaboration with Varian, a Siemens Healthineers (SMMNY) company, to develop novel clinical applications that combine Telix’s theranostic products and external beam radiation therapy, EBRT. Dr. Christian Behrenbruch, Group CEO and Managing Director, Telix, said, “This strategic partnership with Varian represents a transformative opportunity to bring precision imaging into the heart of radiation oncology. Integrating theranostics into EBRT has the potential to improve patient outcomes. And by combining Telix’s innovation in molecular imaging with Varian’s global leadership in cancer treatment technologies, we are building alliances to explore new frontiers in personalized cancer care.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMNY:
- Siemens Healthineers downgraded to Neutral from Outperform at BNPP
- Siemens Healthineers downgraded to Hold from Buy at Deutsche Bank
- Siemens Healthineers price target lowered to EUR 58 from EUR 62 at Citi
- Siemens Healthineers price target lowered to EUR 57 at Deutsche Bank
- Siemens plans to deconsolidate Siemens Healthineers